HRP20251420T1 - Gpr52 modulatorski spojevi - Google Patents
Gpr52 modulatorski spojeviInfo
- Publication number
- HRP20251420T1 HRP20251420T1 HRP20251420TT HRP20251420T HRP20251420T1 HR P20251420 T1 HRP20251420 T1 HR P20251420T1 HR P20251420T T HRP20251420T T HR P20251420TT HR P20251420 T HRP20251420 T HR P20251420T HR P20251420 T1 HRP20251420 T1 HR P20251420T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- disorders
- salt
- disease
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2113186.7A GB202113186D0 (en) | 2021-09-15 | 2021-09-15 | GPR52 Modulator compounds |
| EP22778038.4A EP4401833B1 (en) | 2021-09-15 | 2022-09-15 | Gpr52 modulator compounds |
| PCT/GB2022/052328 WO2023041909A1 (en) | 2021-09-15 | 2022-09-15 | Gpr52 modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20251420T1 true HRP20251420T1 (hr) | 2026-01-02 |
Family
ID=78149263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251420TT HRP20251420T1 (hr) | 2021-09-15 | 2022-09-15 | Gpr52 modulatorski spojevi |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240376070A1 (enExample) |
| EP (1) | EP4401833B1 (enExample) |
| JP (1) | JP2024535860A (enExample) |
| KR (1) | KR20240058852A (enExample) |
| CN (1) | CN117999258A (enExample) |
| AU (1) | AU2022348201A1 (enExample) |
| CA (1) | CA3232606A1 (enExample) |
| CL (1) | CL2024000742A1 (enExample) |
| DK (1) | DK4401833T3 (enExample) |
| ES (1) | ES3053759T3 (enExample) |
| FI (1) | FI4401833T3 (enExample) |
| GB (1) | GB202113186D0 (enExample) |
| HR (1) | HRP20251420T1 (enExample) |
| IL (1) | IL311015A (enExample) |
| LT (1) | LT4401833T (enExample) |
| MX (1) | MX2024003248A (enExample) |
| PL (1) | PL4401833T3 (enExample) |
| PT (1) | PT4401833T (enExample) |
| RS (1) | RS67399B1 (enExample) |
| SI (1) | SI4401833T1 (enExample) |
| SM (1) | SMT202500449T1 (enExample) |
| WO (1) | WO2023041909A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4139284A1 (en) | 2020-04-22 | 2023-03-01 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| WO2025252061A1 (zh) * | 2024-06-04 | 2025-12-11 | 海思科医药集团股份有限公司 | 一种gpr52激动剂及其在医药上的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2009107391A1 (ja) * | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| MX373876B (es) | 2015-04-29 | 2020-03-26 | Arena Pharm Inc | 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. |
| CN111094278B (zh) * | 2017-09-13 | 2023-07-14 | 诺华股份有限公司 | 二苯基衍生物及其用途 |
| CN114650992A (zh) * | 2019-11-08 | 2022-06-21 | 赫普泰雅治疗有限公司 | Gpr52调节剂化合物 |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
-
2021
- 2021-09-15 GB GBGB2113186.7A patent/GB202113186D0/en not_active Ceased
-
2022
- 2022-09-15 KR KR1020247006746A patent/KR20240058852A/ko active Pending
- 2022-09-15 PL PL22778038.4T patent/PL4401833T3/pl unknown
- 2022-09-15 DK DK22778038.4T patent/DK4401833T3/da active
- 2022-09-15 SI SI202230201T patent/SI4401833T1/sl unknown
- 2022-09-15 US US18/689,590 patent/US20240376070A1/en active Pending
- 2022-09-15 AU AU2022348201A patent/AU2022348201A1/en active Pending
- 2022-09-15 SM SM20250449T patent/SMT202500449T1/it unknown
- 2022-09-15 HR HRP20251420TT patent/HRP20251420T1/hr unknown
- 2022-09-15 IL IL311015A patent/IL311015A/en unknown
- 2022-09-15 ES ES22778038T patent/ES3053759T3/es active Active
- 2022-09-15 CA CA3232606A patent/CA3232606A1/en active Pending
- 2022-09-15 PT PT227780384T patent/PT4401833T/pt unknown
- 2022-09-15 JP JP2024516935A patent/JP2024535860A/ja active Pending
- 2022-09-15 WO PCT/GB2022/052328 patent/WO2023041909A1/en not_active Ceased
- 2022-09-15 EP EP22778038.4A patent/EP4401833B1/en active Active
- 2022-09-15 RS RS20251139A patent/RS67399B1/sr unknown
- 2022-09-15 LT LTEPPCT/GB2022/052328T patent/LT4401833T/lt unknown
- 2022-09-15 CN CN202280062419.2A patent/CN117999258A/zh active Pending
- 2022-09-15 MX MX2024003248A patent/MX2024003248A/es unknown
- 2022-09-15 FI FIEP22778038.4T patent/FI4401833T3/fi active
-
2024
- 2024-03-13 CL CL2024000742A patent/CL2024000742A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023041909A1 (en) | 2023-03-23 |
| IL311015A (en) | 2024-04-01 |
| SMT202500449T1 (it) | 2026-01-12 |
| CL2024000742A1 (es) | 2024-09-27 |
| US20240376070A1 (en) | 2024-11-14 |
| JP2024535860A (ja) | 2024-10-02 |
| PL4401833T3 (pl) | 2026-02-16 |
| LT4401833T (lt) | 2025-12-10 |
| MX2024003248A (es) | 2024-04-02 |
| DK4401833T3 (da) | 2025-11-17 |
| RS67399B1 (sr) | 2025-11-28 |
| ES3053759T3 (en) | 2026-01-26 |
| KR20240058852A (ko) | 2024-05-07 |
| AU2022348201A1 (en) | 2024-03-28 |
| EP4401833B1 (en) | 2025-10-22 |
| EP4401833A1 (en) | 2024-07-24 |
| GB202113186D0 (en) | 2021-10-27 |
| PT4401833T (pt) | 2025-11-14 |
| SI4401833T1 (sl) | 2026-01-30 |
| CA3232606A1 (en) | 2023-03-23 |
| FI4401833T3 (fi) | 2025-11-25 |
| CN117999258A (zh) | 2024-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515515A (ja) | カイラルスピロ環ホスフィン−窒素−硫黄三座配位子およびその調製方法と応用 | |
| HRP20241375T1 (hr) | Spojevi modulatora gpr52 | |
| WO2018103509A1 (zh) | 含连续季碳中心环丙烷氨基磷酸酯类化合物的合成方法 | |
| CN106220533B (zh) | 一种利用酮、胺和二氧化碳合成氨基甲酸酯的方法 | |
| CN109651225B (zh) | 一种1-甲基-3-吗啡啉基-4-芳巯基马来酰亚胺化合物的制备方法 | |
| CN111393350A (zh) | 一种n-甲基-3-取代苄巯基-4-吗啉基马来酰亚胺化合物的合成方法 | |
| JP2024535860A5 (enExample) | ||
| FI4401833T3 (fi) | Gpr52:n muuntajayhdisteitä | |
| ES2849425T3 (es) | Método de fabricación de alcohol de cadena larga de ciclohexenona de alta pureza | |
| CN103664821B (zh) | 一种基于邻氨基苯硫酚环化的苯并噻唑类化合物制备方法 | |
| ES2272786T3 (es) | Procedimiento para la sintesis selectiva de trietilendiamina. | |
| CN111440109B (zh) | 一种n-甲基-3-甲巯基-4-胺基马来酰亚胺化合物的制备方法 | |
| Herndon et al. | Pericyclic reactions of cyclopropylcarbene-chromium complexes | |
| CN105693598A (zh) | 一种铱催化氢化合成3-哌啶酮衍生物的方法 | |
| RU2024109992A (ru) | Соединения-модуляторы gpr52 | |
| CN104650025B (zh) | 一种苯并氧杂环庚三烯类化合物的合成方法 | |
| CN104262122B (zh) | 一种1，4-丁烯二酮类化合物的合成方法 | |
| CN106316953A (zh) | 一种6-氰基菲啶类化合物的合成方法 | |
| CN110845466A (zh) | 氧杂环壬二烯衍生物、其药物组合物、其制备方法及用途 | |
| TW201410697A (zh) | 以無溶劑製程製備環磷醯胺之方法 | |
| Pinna et al. | Synthesis, modelling, and μ-opioid receptor affinity of N-3 (9)-arylpropenyl-N-9 (3)-propionyl-3, 9-diazabicyclo [3.3. 1] nonanes | |
| CN111548299B (zh) | 一种n-甲基-3-苄巯基-4-胺基马来酰亚胺化合物的制备方法 | |
| MX2008015050A (es) | Proceso para sintetizar compuestos de piperazina-piperidina. | |
| CN106749078B (zh) | 一种2-亚胺基恶唑的合成方法 | |
| CN107641076A (zh) | 一种菲醌类化合物的合成方法 |